title: Irinotecan in cervical cancer.
abstract: Several studies have evaluated the use of irinotecan (CPT-11 [Camptosar]), a topoisomerase inhibitor, in the treatment of refractory or recurrent cervical cancer. Various schedules have been used. Response rates have ranged from 13% to 20%. One phase I study of the combination of cisplatin (Platinol) and irinotecan has been completed. Toxicities have been hematologic and gastrointestinal. The latter remains problematic. Further studies of irinotecan in combination with other drugs, particularly cisplatin, are recommended.
authors.affiliation: Section of Gynecologic Medical Oncology, UT M.D. Anderson Cancer Center, Houston, Texas, USA.
authors.forename: J J
authors.initials: JJ
authors.lastname: Kavanagh
authors.forename: C F
authors.initials: CF
authors.lastname: Verschraegen
authors.forename: A P
authors.initials: AP
authors.lastname: Kudelka
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D000077146:Irinotecan; D059004:Topoisomerase I Inhibitors; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy*
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D059004:Topoisomerase I Inhibitors; D000077146:Irinotecan; D002166:Camptothecin